| B2M |
B2M, CDABP0092, HDCMA22P: Beta-2-microglobulin precursor [Contains: Beta-2-micro |
MICB |
MICB, DAQB-72H16.3-001, DASS-81K16.3-001: MHC class I polypeptide-related sequen |
3.997 |
Evidence |
|
| B2M |
B2M, CDABP0092, HDCMA22P: Beta-2-microglobulin precursor [Contains: Beta-2-micro |
HLA-C |
IPI00719394 |
3.997 |
Evidence |
|
| B2M |
B2M, CDABP0092, HDCMA22P: Beta-2-microglobulin precursor [Contains: Beta-2-micro |
HLA-B |
HLA-B, HLAB: HLA class I histocompatibility antigen, B-53 alpha chain precursor |
3.997 |
Evidence |
O
|
| B2M |
B2M, CDABP0092, HDCMA22P: Beta-2-microglobulin precursor [Contains: Beta-2-micro |
HLA-DPB1 |
HLA class II histocompatibility antigen, SB beta chain (Fragment) |
3.997 |
Evidence |
|
| KDR |
KDR, FLK1: Vascular endothelial growth factor receptor 2 precursor |
BLNK |
IPI00718885 |
3.997 |
Evidence |
|
| NULL |
HLA-B, HLAB: HLA class I histocompatibility antigen, B-50 alpha chain precursor |
B2M |
B2M, CDABP0092, HDCMA22P: Beta-2-microglobulin precursor [Contains: Beta-2-micro |
3.997 |
Evidence |
|
| HLA-DMB |
HLA-DMB, DMB, RING7: HLA class II histocompatibility antigen, DM beta chain prec |
HLA-C |
IPI00719394 |
3.997 |
Evidence |
|
| HLA-DMB |
HLA-DMB, DMB, RING7: HLA class II histocompatibility antigen, DM beta chain prec |
HLA-A |
HLA-A, HLAA: HLA class I histocompatibility antigen, A-80 alpha chain precursor |
3.997 |
Evidence |
|
| HLA-DMB |
HLA-DMB, DMB, RING7: HLA class II histocompatibility antigen, DM beta chain prec |
NULL |
HLA-B, HLAB: HLA class I histocompatibility antigen, B-39 alpha chain precursor |
3.997 |
Evidence |
|
| ERBB3 |
ERBB3, HER3: Receptor tyrosine-protein kinase erbB-3 precursor |
TNS1 |
TNS1, TNS: Tensin-1 |
3.997 |
Evidence |
|
| HLA-A |
HLA-A, HLAA: HLA class I histocompatibility antigen, A-11 alpha chain precursor |
B2M |
B2M, CDABP0092, HDCMA22P: Beta-2-microglobulin precursor [Contains: Beta-2-micro |
3.997 |
Evidence |
|
| KIT |
KIT: Mast/stem cell growth factor receptor precursor |
FES |
Proto-oncogene c-fes variant 3 |
3.997 |
Evidence |
|
| FYN |
FYN: Proto-oncogene tyrosine-protein kinase Fyn |
FES |
Proto-oncogene c-fes variant 3 |
3.997 |
Evidence |
|
| FYN |
FYN: Proto-oncogene tyrosine-protein kinase Fyn |
BLNK |
IPI00004549 |
3.997 |
Evidence |
|
| ERBB2 |
ERBB2, HER2, NEU, NGL: Receptor tyrosine-protein kinase erbB-2 precursor |
TNS1 |
TNS1, TNS: Tensin-1 |
3.997 |
Evidence |
|
| HLA-B |
HLA-B, HLAB: HLA class I histocompatibility antigen, B-7 alpha chain precursor |
NULL |
HLA-B, HLAB: HLA class I histocompatibility antigen, B-38 alpha chain precursor |
3.997 |
Evidence |
|
| UBE2A |
UBE2A, RAD6A: Ubiquitin-conjugating enzyme E2 A |
UBR1 |
UBR1: E3 ubiquitin-protein ligase UBR1 |
3.995 |
Evidence |
|
| RAB8A |
RAB8A: RAB8A protein |
RAB1A |
RAB1A, RAB1: Ras-related protein Rab-1A |
3.99 |
Evidence |
|
| COPS6 |
COPS6, CSN6, HVIP: COP9 signalosome complex subunit 6 |
COPS8 |
COPS8, CSN8: COP9 signalosome complex subunit 8 |
3.987 |
Evidence |
|
| BAK1 |
IPI00003352 |
BAD |
BAD, BBC6, BCL2L8: Bcl2 antagonist of cell death |
3.987 |
Evidence |
|
| PRKCG |
PRKCG, PKCG: Protein kinase C gamma type |
PDLIM5 |
PDLIM5, ENH: PDZ and LIM domain protein 5 |
3.985 |
Evidence |
O
|
| DSTN |
DSTN, ACTDP, DSN: Destrin |
HIST2H2BE |
HIST2H2BE, H2BFQ: Histone H2B type 2-E |
3.985 |
Evidence |
|
| HPCAL1 |
HPCAL1, BDR1: Hippocalcin-like protein 1 |
K-ALPHA-1 |
TUBA1B: Tubulin alpha-1B chain |
3.985 |
Evidence |
|
| MYCN |
MYCN, NMYC: N-myc proto-oncogene protein |
MAP2K2 |
MAP2K2, MEK2, MKK2, PRKMK2: Dual specificity mitogen-activated protein kinase ki |
3.985 |
Evidence |
|
| MAP2K1 |
MAP2K1, MEK1, PRKMK1: Dual specificity mitogen-activated protein kinase kinase 1 |
BAD |
BAD, BBC6, BCL2L8: Bcl2 antagonist of cell death |
3.982 |
Evidence |
|